Stephen Hoge

Stephen Hoge sells 53,336 MRNA shares at $67.60; stock now -26.2% from 52-week high amid -39.9% revenue decline

Stephen Hoge, Moderna's President, executed a scheduled sale of 53,336 shares at $67.60 on 2026-07-15 under a pre-arranged 10b5-1 trading plan adopted 2025-11-13, reducing his non-derivative holdings by 3.5% to 1,483,848 shares. The sale occurred as MRNA stock is down 26.2% from its 52-week high of $85.60, while the company reported a net loss of $-1.3B for the most recent full fiscal year and annual revenue declined 39.9% year-over-year. His prior five sales at MRNA show mixed timing outcomes: two recent 2026 sales (June and May) posted 30-day gains of 32.9% and 3.1%, respectively, but two 2024 sales resulted in 90-day declines of -51.9% and -50.6%. This transaction's execution through a scheduled 10b5-1 plan removes discretionary timing from consideration; investors should focus on the company's deteriorating financial profile—the net loss and sharp revenue contraction—rather than interpreting the sale as a timing signal.

Moderna President Hoge sold 53,336 shares ($2.7M) on 2026-06-15 via pre-arranged 10b5-1 plan; stock up 28.5% in 30 days post-sale.

Stephen Hoge, Moderna's President, sold 53,336 shares at $51.37 on 2026-06-15, reducing non-derivative holdings to 1,483,848 shares (a -3.5% reduction from 1,537,184 shares). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-13, making it a scheduled divestment rather than a discretionary trade. Since the sale, MRNA has risen +28.5% over 30 days, trading at $61.80 (within 0.8% of its 52-week high of $62.30). Notably, Hoge's prior open-market trades across all tickers show a cross-ticker track record averaging -2.4% return 90 days after sells, and his MRNA-specific history includes five prior sales with mixed results, most recently a May 2026 sale that saw +3.1% gains in the following 30 days. The company's fundamentals remain challenged: Moderna generated revenue of $389,000,000.00 in the latest quarter but posted a net loss of $-1,343,000,000.00 for the full fiscal year, with annual revenue declining -39.9% year-over-year. The insider retains substantial derivative holdings (53,336 shares via stock options), meaning his overall economic exposure to MRNA remains material despite this partial non-derivative sale.

MRNA President Hoge sells 53,336 shares at $48.40; stock down 10.4% in 30 days, company lost $1.3B in last year.

Stephen Hoge, President of Moderna, sold 53,336 shares (53.3K shares) on 2026-05-15 at $48.40, reducing his holdings by 3.5% to 1.48M shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-13 and therefore represents a scheduled trade rather than a discretionary decision. The sale occurs against a backdrop of negative recent price momentum, with MRNA down 10.4% over the prior 30 days and trading 19.2% below its 52-week high of $59.55. More significantly, Moderna's fundamentals show deterioration: the company reported a net loss of $1.3B in its most recent full year and annual revenue declined 39.9% year-over-year, reflecting the sharp contraction in pandemic-related demand. His prior five trades at MRNA show mixed outcomes, including a notable 90-day loss of 51.9% following a July 2024 sale, but this current transaction is scheduled under a pre-arranged plan rather than a discretionary market response.

MRNA president Hoge sells 160,009 shares at $48.84 via pre-arranged 10b5-1 plan

Hoge Stephen, President of Moderna, sold 160,009 shares at $48.84 on 2026-02-23 under a 10b5-1 trading plan adopted on 2025-11-13, reducing his holdings from 1,617,436 shares to 1,457,427 shares. The sale represents a scheduled, predetermined transaction rather than a discretionary insider decision, limiting its value as a signal of current conviction or market outlook. Post-transaction holdings of 1,457,427 shares remain substantial, indicating continued significant equity exposure to the company. The pre-arranged plan structure means the timing and execution were determined months prior and do not reflect a contemporaneous assessment of valuation or business prospects.

Moderna President Stephen Hoge sold 15,000 shares at $121.12 on 2024-07-15, reducing stake to 1.44M shares as stock fell -24.9% from 52-week high.

Stephen Hoge sold 15,000 shares (1.0% of pre-transaction holdings) at $121.12, maintaining a substantial 1.44M share stake in Moderna. The sale occurred at a price now -24.9% below the 52-week high of $166.61, and the stock has declined -10.6% in the 30 days since the transaction. At his prior trades at MRNA, Hoge achieved 0 of 3 measurable well-timed 90-day outcomes (averaging +40.2% gain after selling), indicating his recent sales have not preceded sharp declines. Moderna's fundamentals show acute pressure: annual revenue contracted -64.4% year-over-year, the company reported a -$1.2B net loss in its most recent full fiscal year, and quarterly revenue stands at only $167.0M against a $48.0B market cap. The continued selling despite a depressed valuation and persistent unprofitability suggests ongoing position reduction rather than a high-conviction hold at current levels.

Moderna president Hoge sold 15,000 shares at $138.16 for $2.1M; stock down 20.0% from 52-week high, company unprofitable with -64.4% annual revenue decline.

Stephen Hoge sold 15,000 shares (15.0K shares) of Moderna at $138.16 on 2024-06-17, reducing his holdings from 1,472,089 to 1,457,089 shares. The sale occurred when MRNA was trading $133.27 currently, down 20.0% from its 52-week high of $166.61. Moderna's fundamentals show significant deterioration: the company reported a net loss of $-1,175,000,000.00 ($-1.2B) in its most recent full fiscal year, annual revenue contracted -64.4%, and latest-quarter revenue was $167,000,000.00 ($167.0M). In context of the same-ticker history, Hoge's prior five sales at MRNA (spanning 2024-02-16 through 2024-05-15) showed strong subsequent price appreciation at the 90-day measurement window (three measurable outcomes ranging from +40.8% to +63.3%), suggesting his prior sells at this ticker have not preceded declines. The current sale follows the same pattern: no 10b5-1 trading plan disclosure is noted, leaving timing interpretation valid.